Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study

Harvard University, Cambridge, Massachusetts, United States
British Journal of Clinical Pharmacology (Impact Factor: 3.88). 04/2007; 63(4):431-7. DOI: 10.1111/j.1365-2125.2006.02780.x
Source: PubMed


Antidepressant use in East Asia is poorly documented. We compared patients given newer and older antidepressants to test the hypothesis, suggested in the literature, that use of newer antidepressants is associated with treatment settings rather than specific diagnostic categories.
We compared rates of use of older (pre1990) vs. newer antidepressants among 1898 patients identified as antidepressant treated at 21 centres in five East Asian countries (China, Japan, Korea, Singapore, Taiwan) in 2003. Demographics, treatment setting and clinical factors associated with preferential use of newer drugs were tested in univariate and multivariate analyses.
Newer antidepressants were included in the treatment regimens of 67.5% (N = 1282/1898) of study subjects. Prescription for newer antidepressants was significantly associated with younger age (z = -4.55, d.f. = 1888, P < 0.001), hospitalization [odds ratio (OR) 1.32, 95% confidence interval (CI) 1.07, 1.64, P < 0.01] and treatment within psychiatric hospitals (OR 1.59, 95% CI 1.27, 2.00, P < 0.001). On multivariate analyses, treatment with newer antidepressants was independently associated with younger age (P < 0.001), country (P < 0.001) and treatment within private hospitals (P < 0.001), but not with sex or diagnosis of affective or anxiety disorders (all P > 0.1).
Demographic factors and treatment settings appear to influence antidepressant choice more than clinical factors such as diagnosis.

Download full-text


Available from: Norman Sartorius, Oct 04, 2015
113 Reads
  • Source
    • "In recent decades, selective serotonin reuptake inhibitors (SSRIs) have become the first-line antidepressant drug treatment of depression and replaced tricyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOI) due to fewer side-effects and ease of use in Western countries [1,2]. Also, SSRIs have become the dominant subcategory of antidepressants in China [3–5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Selective serotonin reuptake inhibitors (SSRIs) have become the most frequently used antidepressants in China in recent decades. This systematic review and meta-analysis examined the efficacy and tolerability of SSRIs in Chinese studies and the quality of Chinese randomized controlled trials. Major Western and Chinese electronic databases were searched for double-blind, parallel group randomised controlled trials (RCTs) comparing SSRIs (fluoxetine, citalopram, escitalopram, fluvoxamine, paroxetine, or sertraline) with other antidepressants such as SSRI, Selective Noradrenaline Reuptake Inhibitor (SNRI), tricyclic antidepressant (TCA), Traditional Chinese Medicine (TCM) and/or placebo. Response, remission, and dropout rates due to side effects were defined as primary outcomes. Mean total Hamilton Rating Scale of Depression (HAMD) scores at endpoint, overall dropout rates and total Treatment Emergent Symptom Scale (TESS) scores were defined as secondary outcomes. Data were combined with random effects models. Risk of bias was assessed by the Cochrane evaluation tool. Quality of reports was assessed by the fulfilment of Consolidated Standards of Reporting Trial (CONSORT) items. A total of 71 studies were included. Only one study was listed in both Chinese and Western databases. SSRIs were found to be more effective than TCAs. No significant differences were observed regarding dropout rates due to side effects. Using the Cochrane risk of bias tool, adequate methods of sequence generation were described in 16 (23%) studies. All authors failed to report trial registration. Informed consent, sources of funding, email address, protocol, and limitations were also not mentioned in most studies. However, reporting quality improved steadily between 1996 and 2013. In light of the low trial quality, the findings of a significant advantage of SSRI over TCA in terms of response rate and remission rate should be replicated by large high-quality Chinese studies.
    BMC Psychiatry 08/2014; 14(1):245. DOI:10.1186/s12888-014-0245-4 · 2.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present review focuses on the pharmacoepidemiological issues of psychotropic drug use in countries within east Asia, with special emphasis on antipsychotic, antidepressant and benzodiazepine prescriptions. Pharmacogenetic studies in different ethnic groups are also reviewed. Recent studies have revealed the prevalence of antipsychotic polytherapy (defined as the use of more than one antipsychotic; up to 45.7%), less conservative antipsychotic use (defined as the use of more than 1000 mg/day chlorpromazine equivalents; up to 17.9%) and depot antipsychotic use (up to 15.3%) in different populations in east Asia. Clozapine is commonly prescribed (up to 60%) in China. There is a trend of increasing second-generation antipsychotic use in east Asian countries. Up to 67.5% of patients received newer antidepressants such as selective serotonin reuptake inhibitors. Benzodiazepine medications are used in up to 29.9% of study populations. Socioeconomic factors appear to be one of the major common factors that affect the prescription of antipsychotics and newer antidepressants. Pharmacogenetic factors associated with antipsychotic response, weight gain and extrapyramidal side effects have been examined. Treatment adherence and pharmacoeconomic factors are relatively understudied. Future studies on prescribing trends of antipsychotics and antidepressants need to focus on children, adolescent and elderly patient populations, the impact of changing prescription trends and the long-term effects on patients and their caregivers, as well as pharmacogenetic factors, which can potentially pave the way for better and more individualized prescription of psychotropic drugs in east Asia.
    Current opinion in psychiatry 12/2008; 21(6):645-50. DOI:10.1097/YCO.0b013e32830e6dc4 · 3.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A multi-environment turbulent combustion model, originally developed for Reynolds averaged Navier–Stokes equations (RANS), was extended to large eddy simulation (LES) and was used to model a bluff-body stabilized flame series (HM1 and HM3) that ranges from near equilibrium to near global extinction. The multi-environment filtered density function model (MEFDF) depicts the filtered density function (FDF) as a weighted summation of a small number of multi-dimensional Dirac delta functions in composition space. It is derived from the transport FDF equation using the direct quadrature method of moments (DQMOM). The MEFDF method with multiple reactive scalars retains the unique property of the joint FDF model of treating the chemical source term exactly. It was coupled with a 19-species reduced mechanism based on quasi-steady-state assumption and an In Situ adaptive tabulation (ISAT) algorithm for chemical source term integration. The model successfully captures the level of local extinction of the two flames exhibited in experiment. The predicted radial profiles of mixture fraction, temperature and CO mass fraction are in good agreement with measurements. The current work highlights the potential of LES/MEFDF approach as a tool for modeling of turbulent flame stability and combustion dynamics as well as pollutant emissions.
    Proceedings of the Combustion Institute 01/2011; 33(1):1347-1353. DOI:10.1016/j.proci.2010.07.005 · 2.26 Impact Factor
Show more